Please assess the completion status of the following clinical trial:

Trial Title: The Lira Pump Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes ≥ 1 year~* BMI \> 25 kg/m2~* Insulin pump ≥ 1 year~* HbA1c \> 58 mmol/mol~* Use of carbohydrate counting and the insulin pump bolus calculator~Exclusion Criteria:~* Gastroparesis~* Impaired renal function (eGFR \< 60 ml/min/1.73m2)~* Liver disease with ALAT \> 2.5 times the upper limit of the reference interval~* Acute or chronic pancreatitis or history of chronic pancreatitis or idiopathic acute pancreatitis~* Inflammatory bowel disease~* History of cancer (except basal cell skin cancer) which in the investigators opinion could interfere with the results of the trial, or cancer during the past 5 years~* Thyroid adenoma~* Subjects with personal or family history of MTC or MEN2~* Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start~* Known or suspected alcohol or drug abuse~* Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation~* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods.~* Simultaneous participation in any other clinical intervention trial~* Known or suspected hypersensitivity to Liraglutide~* Inability to understand the patient information and to give informed consent~* Acute treatment required proliferative retinopathy or maculopathy (macular oedema)~* Any Cardiac disorder which in the investigators opinion could interfere with the safety and results of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Liraglutide; daily subcutaneous injection; 1.8 mg; 6 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo; daily subcutaneous injection; 1.8 mg; 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).